RxDoctor Payments Data

Paris Charilaou, MD

Gastroenterology · Charlotte, NCNPI 1457734659

Payments from drug & device makers

$67,654in general payments, 2019–2025

Across 196 payments — averaging $345.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$57K
  • AbbVie$5K
  • Pfizer$3K
  • Johnson & Johnson$968
  • Takeda Pharmaceuticals U.S.A., Inc.$402
  • Janssen Scientific Affairs, LLC$324
  • plus $541 from 6 others

What the payments were for

  • Consulting fees$5,80049%
  • Travel & lodging$9538%
  • Food & beverage$4,85041%
  • Education$2852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,654 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,636
Medicare patients
103
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa32$628,341
RinvoqUpadacitinib14$142,266
MotegrityPrucalopride Succinate13$7,007
Mesalamine25$4,696
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,402
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag20$2,488
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C14$1,996
Ciprofloxacin Hcl25$1,204
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl43$742
Omeprazole44$647
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg17$352
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl14$215
Ondansetron Hcl13$122
Dicyclomine Hcl11$96
Promethazine Hcl18$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$5,267$142,26614 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$402$7,00713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →